Catherine Jennings: Marking Today as an Important Step Forward for Patients With PE
Catherine Jennings, President, Peripheral Vascular at Boston, shared a post on LinkedIn:
“Today marks an important step forward for patients with pulmonary embolism (PE) and for the future of PE care.
This morning at ACC 26, we presented positive results from the HI-PEITHO randomized clinical trial, demonstratinge that the EKOS Endovascular System plus anticoagulation was superior to the current standard of care, anticoagulation alone, for the treatment of acute intermediate-risk PE.
The study, which was also simultaneously published in The New England Journal of Medicine, met its primary endpoint of PE-related mortality, non-fatal hemodynamic cardiorespiratory decompensation or collapse and non-fatal symptomatic recurrence of PE within seven days (4.0% vs. 10.3%; p=0.005), representing a 61% reduction in primary endpoint events.
PE is the third leading cause of cardiovascular mortality, impacting nearly one million patients annually in the U.S. and Europe. Despite that burden, relatively few patients today receive interventional therapy.
As the largest global randomized controlled trial comparing an interventional therapy to anticoagulation alone for acute PE using clinically meaningful endpoints, the HI-PEITHO study provides important clinical evidence to help inform treatment decisions and potentially influence future care pathways.
We are proud of what the HI-PEITHO study represents for patients, physicians and the future of PE care.”
Title: Ultrasound-Facilitated, Catheter-Directed Fibrinolysis for Acute Pulmonary Embolism
Authors: Kenneth Rosenfield, Frederikus A. Klok, Gregory Piazza, Andrew S. P. Sharp, Fionnuala Ní Áinle, Michael R. Jaff, Stefano Barco, Samuel Z. Goldhaber, Nils Kucher, Irene M. Lang, Irene Schmidtmann, Keith M. Sterling, Aleksander Araszkiewicz, Vishal Arora, Rafael Cires-Drouet, John Coghlan, Lukas Hobohm, Wulf D. Ito, Kurt Jacobson, Christoph Kaiser, Grzegorz Kopec, Kristin Marx, Samuel McElwee, Nicolas Meneveau, Peter Monteleone, Jose M. Montero-Cabezas, Christoph B. Olivier, John Park, Marek Roik, Rahul Sakhuja, Andi Tego, Markus Theurl, Gautam Visveswaran, Jan Albert Vos, Michael N. Young, Federico M. Asch, Stavros V. Konstantinides
Read the Full Article on The New England Journal of Medicine
Stay updated on all scientific advances with Hemostasis Today.
-
Jun 8, 2026, 03:05Shamsunisha Yusuff: Iron Down, Platelets Up in a Young CBC ?
-
Jun 8, 2026, 03:03Samwel Mikaye: D-Dimer – A Marker of Blood Clot Breakdown
-
Jun 8, 2026, 02:59Vinita Madhuri: Our Engagement, A Lifeline for Thalassemia Patients
-
Jun 7, 2026, 22:11Lucia Härtel: Exercise, IL-10 Signaling, and Post-Stroke Brain Plasticity
-
Jun 7, 2026, 19:35Ashish Pemawat: Is the 4.5-Hour Thrombolysis Window Becoming Less Relevant?
-
Jun 7, 2026, 18:25Nita Radhakrishnan: Every Child Cured Is a Reminder of What Can Be Achieved When We Work Together
-
Jun 7, 2026, 18:24Yvette Fairfax: Wiskott-Aldrich Gene Therapy Changes Immunity, but Affordability May Determine Survival
-
Jun 7, 2026, 18:21Gulab Makwana: Complete Guide to Clotting Factors – Understanding the Coagulation System
-
Jun 7, 2026, 18:15Chuhan Dong: Presenting My Research on Antibody-Mediated RBC Clearance at Canadian Blood Services